Vimarsana
Biggest News Aggregation in the World

Page 17 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia - Vimarsana News

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia

BeiGene’s BTKi is approved in more than 65 markets globally ... | May 30, 2023

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio - Vimarsana News

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor... | May 25, 2023

BeiGene to Present at Upcoming Investor Conferences - Vimarsana News

BeiGene to Present at Upcoming Investor Conferences

BeiGene , a global biotechnology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit... | May 24, 2023

StockNews.com Initiates Coverage on BeiGene (NASDAQ:BGNE) - Vimarsana News

StockNews.com Initiates Coverage on BeiGene (NASDAQ:BGNE)

StockNews.com assumed coverage on shares of BeiGene (NASDAQ:BGNE – Get Rating) in a research report report published on Thursday morning. The brokerage issued a hold rating on the stock. Several other equities research analysts have also weighed in on BGNE. Cowen lifted their price target on BeiGene from $213.00 to $262.00 and gave the company […]

BeiGene (NASDAQ:BGNE) Now Covered by StockNews.com - Vimarsana News

BeiGene (NASDAQ:BGNE) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of BeiGene (NASDAQ:BGNE – Get Rating) in a report published on Thursday. The firm issued a hold rating on the stock. Several other brokerages have also issued reports on BGNE. Guggenheim reiterated a buy rating and issued a $350.00 price target on shares of BeiGene in a research note on […]